Current status of clinical trials of m-AMSA, dihydroxyanthracenedione, and deoxycoformycin.

J. S. Macdonald, S. Marsoni, S. Bruno, D. Poster

Research output: Contribution to journalArticle

Abstract

The current status of three drugs of clinical interest to the National Cancer Institute is reviewed. m-AMSA, a drug with a wide spectrum of activity in murine tumors, is now in phase II trial and has shown itself to have a high order of activity in acute nonlymphocytic leukemia. Dihydroxyanthracenedione, a compound with some of the characteristics of anthracyclines but with no cardiac toxicity in animal toxicology studies, is in phase I evaluation. Deoxycoformycin, an adenosine analog which is a potent inhibitor of adenosine deaminase, has shown moderate activity in acute leukemia patients in phase I trials, and has the potential to produce synergistic antitumor toxicity when used with arabinofuranosyladenine.

Original languageEnglish
Pages (from-to)323-330
Number of pages8
JournalRecent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
Volume80
Publication statusPublished - 1982

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Current status of clinical trials of m-AMSA, dihydroxyanthracenedione, and deoxycoformycin.'. Together they form a unique fingerprint.

  • Cite this